Origin and pathogenesis of nodular lymphocyte–predominant Hodgkin lymphoma as revealed by global gene expression analysis

The pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) and its relationship to other lymphomas are largely unknown. This is partly because of the technical challenge of analyzing its rare neoplastic lymphocytic and histiocytic (L&H) cells, which are dispersed in an abundant nonneoplastic cellular microenvironment. We performed a genome-wide expression study of microdissected L&H lymphoma cells in comparison to normal and other malignant B cells that indicated a relationship of L&H cells to and/or that they originate from germinal center B cells at the transition to memory B cells. L&H cells show a surprisingly high similarity to the tumor cells of T cell-rich B cell lymphoma and classical Hodgkin lymphoma, a partial loss of their B cell phenotype, and deregulation of many apoptosis regulators and putative oncogenes. Importantly, L&H cells are characterized by constitutive nuclear factor kappaB activity and aberrant extracellular signal-regulated kinase signaling. Thus, these findings shed new light on the nature of L&H cells, reveal several novel pathogenetic mechanisms in NLPHL, and may help in differential diagnosis and lead to novel therapeutic strategies.

[1]  Y. Natkunam,et al.  Selective loss of B‐cell phenotype in lymphocyte predominant Hodgkin lymphoma , 2007, The Journal of pathology.

[2]  K. Bland,et al.  The human CD77− B cell population represents a heterogeneous subset of cells comprising centroblasts, centrocytes, and plasmablasts, prompting phenotypical revision , 2006, The Journal of Immunology.

[3]  S. Tangye,et al.  Kinetics of Human B Cell Behavior and Amplification of Proliferative Responses following Stimulation with IL-211 , 2006, The Journal of Immunology.

[4]  C. Borrebaeck,et al.  The Human CD77− B Cell Population Represents a Heterogeneous Subset of Cells Comprising Centroblasts, Centrocytes, and Plasmablasts, Prompting Phenotypical Revision1 , 2006, The Journal of Immunology.

[5]  E. Campo,et al.  Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphoma. , 2006, Blood.

[6]  R. Siebert,et al.  Aberrant expression of ID2, a suppressor of B-cell-specific gene expression, in Hodgkin's lymphoma. , 2006, The American journal of pathology.

[7]  David E Levy,et al.  STAT1 acts as a tumor promoter for leukemia development. , 2006, Cancer cell.

[8]  Hidetoshi Shimodaira,et al.  Pvclust: an R package for assessing the uncertainty in hierarchical clustering , 2006, Bioinform..

[9]  Richard Simon,et al.  Molecular diagnosis of Burkitt's lymphoma. , 2006, The New England journal of medicine.

[10]  E. Schuuring,et al.  Cortactin affects cell migration by regulating intercellular adhesion and cell spreading. , 2006, Experimental cell research.

[11]  H. J. Kim,et al.  NF-κB and IKK as therapeutic targets in cancer , 2006, Cell Death and Differentiation.

[12]  Siew Hong Leong,et al.  FAT10 Plays a Role in the Regulation of Chromosomal Stability* , 2006, Journal of Biological Chemistry.

[13]  J. Abramson.  T-cell/histiocyte-rich B-cell lymphoma: biology, diagnosis, and management. , 2006, The oncologist.

[14]  Y. Natkunam,et al.  Loss of CD19 expression in B‐cell neoplasms , 2006, Histopathology.

[15]  P. Fisher,et al.  mda-9/Syntenin: a positive regulator of melanoma metastasis. , 2005, Cancer research.

[16]  E. Wherry,et al.  Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin , 2005, Nature Immunology.

[17]  G. Rabinovich,et al.  The coming of age of galectins as immunomodulatory agents: impact of these carbohydrate binding proteins in T cell physiology and chronic inflammatory disorders , 2005, Annals of the rheumatic diseases.

[18]  R. Siebert,et al.  Molecular cytogenetic analyses of immunoglobulin loci in nodular lymphocyte predominant Hodgkin's lymphoma reveal a recurrent IGH-BCL6 juxtaposition. , 2005, The Journal of molecular diagnostics : JMD.

[19]  S. Shirasawa,et al.  Transformation by Oncogenic RAS Sensitizes Human Colon Cells to TRAIL-induced Apoptosis by Up-regulating Death Receptor 4 and Death Receptor 5 through a MEK-dependent Pathway* , 2005, Journal of Biological Chemistry.

[20]  A. Roessner,et al.  Interactions between human colon carcinoma cells, fibroblasts and monocytic cells in coculture--regulation of cathepsin B expression and invasiveness. , 2005, Cancer letters.

[21]  M. Leroy,et al.  A role for PKCζ in the LPS-induced translocation NF-κB p65 subunit in cultured myometrial cells , 2005 .

[22]  S. Hillion,et al.  Expression of RAGs in Peripheral B Cells outside Germinal Centers Is Associated with the Expression of CD51 , 2005, The Journal of Immunology.

[23]  B. Jungnickel,et al.  Differential expression of activation‐induced cytidine deaminase (AID) in nodular lymphocyte‐predominant and classical Hodgkin lymphoma , 2005, The Journal of pathology.

[24]  K. Savage,et al.  TRAF1 Expression and c-Rel Activation Are Useful Adjuncts in Distinguishing Classical Hodgkin Lymphoma From a Subset of Morphologically or Immunophenotypically Similar Lymphomas , 2005, The American journal of surgical pathology.

[25]  Xiaodong Cheng,et al.  Antiapoptotic effect of serum and glucocorticoid-inducible protein kinase is mediated by novel mechanism activating I{kappa}B kinase. , 2005, Cancer research.

[26]  Y. Tu,et al.  Tracking CD40 signaling during germinal center development. , 2004, Blood.

[27]  T. Golub,et al.  Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. , 2004, Blood.

[28]  Yasodha Natkunam,et al.  Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B-cell derivation. , 2004, Blood.

[29]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[30]  I. H. Engels,et al.  Caspase-2 Can Function Upstream of Bid Cleavage in the TRAIL Apoptosis Pathway* , 2004, Journal of Biological Chemistry.

[31]  M. Stack,et al.  Calcium-induced Matrix Metalloproteinase 9 Gene Expression Is Differentially Regulated by ERK1/2 and p38 MAPK in Oral Keratinocytes and Oral Squamous Cell Carcinoma* , 2004, Journal of Biological Chemistry.

[32]  S. Olson,et al.  Expression of c-FLIP in Classic and Nodular Lymphocyte-Predominant Hodgkin Lymphoma , 2004, Applied immunohistochemistry & molecular morphology : AIMM.

[33]  J. Mandell,et al.  Phosphorylation state-specific antibodies: applications in investigative and diagnostic pathology. , 2003, The American journal of pathology.

[34]  Mamoun Younes,et al.  MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. , 2003, Blood.

[35]  S. Hirohashi,et al.  β‐Catenin mutations in pulmonary blastomas: association with morule formation , 2003, The Journal of pathology.

[36]  H. Stein,et al.  Differential expression and function of A20 and TRAF1 in Hodgkin lymphoma and anaplastic large cell lymphoma and their induction by CD30 stimulation , 2003, The Journal of pathology.

[37]  V. Diehl,et al.  Profiling of Hodgkin’s Lymphoma Cell Line L1236 and Germinal Center B Cells: Identification of Hodgkin’s Lymphoma-specific Genes , 2003 .

[38]  Andrea Califano,et al.  Transcriptional analysis of the B cell germinal center reaction , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[39]  T. Speed,et al.  Summaries of Affymetrix GeneChip probe level data. , 2003, Nucleic acids research.

[40]  V. Diehl,et al.  Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. , 2003, Blood.

[41]  Andrea Califano,et al.  Identification of Hodgkin and Reed-Sternberg cell-specific genes by gene expression profiling. , 2003, The Journal of clinical investigation.

[42]  C. Fellbaum,et al.  Expression patterns of transcription factors in progressively transformed germinal centers and Hodgkin lymphoma , 2003, Virchows Archiv.

[43]  R. Siebert,et al.  Frequent occurrence of BCL6 rearrangements in nodular lymphocyte predominance Hodgkin lymphoma but not in classical Hodgkin lymphoma. , 2003, Blood.

[44]  D. Strumberg,et al.  The Ras-Raf-MEK-ERK Pathway in the Treatment of Cancer , 2002, Oncology Research and Treatment.

[45]  E. Jaffe,et al.  T-Cell/Histiocyte-Rich Large B-Cell Lymphoma: A Heterogeneous Entity With Derivation From Germinal Center B Cells , 2002, The American journal of surgical pathology.

[46]  Kazuyoshi Takeda,et al.  New aspects of natural-killer-cell surveillance and therapy of cancer , 2002, Nature Reviews Cancer.

[47]  G. Niedobitek,et al.  Frequent expression of the Epstein–Barr virus (EBV)‐induced gene, EBI3, an IL‐12 p40‐related cytokine, in Hodgkin and Reed–Sternberg cells , 2002, The Journal of pathology.

[48]  Sulin Wu,et al.  Cytosolic Retention of Phosphorylated Extracellular Signal-Regulated Kinase and a Rho-Associated Kinase-Mediated Signal Impair Expression of p21Cip1/Waf1 in Phorbol 12-Myristate-13- Acetate-Induced Apoptotic Cells , 2002, Molecular and Cellular Biology.

[49]  P. Henkart,et al.  Surface Cathepsin B Protects Cytotoxic Lymphocytes from Self-destruction after Degranulation , 2002, The Journal of experimental medicine.

[50]  Pedro Romero,et al.  Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity , 2002, Oncogene.

[51]  C. Meijer,et al.  Differential Expression of Thymus and Activation Regulated Chemokine and Its Receptor CCR4 in Nodal and Cutaneous Anaplastic Large-Cell Lymphomas and Hodgkin's Disease , 2002, Modern Pathology.

[52]  H. Ling,et al.  The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways. , 2002, The Biochemical journal.

[53]  Martin Vingron,et al.  Variance stabilization applied to microarray data calibration and to the quantification of differential expression , 2002, ISMB.

[54]  A. Diepstra,et al.  Common and differential chemokine expression patterns in rs cells of NLP, EBV positive and negative classical hodgkin lymphomas , 2002, International journal of cancer.

[55]  M. Saji,et al.  Metastin receptor is overexpressed in papillary thyroid cancer and activates MAP kinase in thyroid cancer cells. , 2002, The Journal of clinical endocrinology and metabolism.

[56]  B. Lim,et al.  The Hematopoiesis-Specific GTP-Binding Protein RhoH Is GTPase Deficient and Modulates Activities of Other Rho GTPases by an Inhibitory Function , 2002, Molecular and Cellular Biology.

[57]  A. Veillette.  Faculty Opinions recommendation of Activation of NK cell-mediated cytotoxicity by a SAP-independent receptor of the CD2 family. , 2002 .

[58]  Ulrich Siebenlist,et al.  Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma Cells , 2001, The Journal of experimental medicine.

[59]  M. Colonna,et al.  Cutting Edge: Activation of NK Cell-Mediated Cytotoxicity by a SAP-Independent Receptor of the CD2 Family1 , 2001, The Journal of Immunology.

[60]  Marcel Leist,et al.  Cathepsin B Acts as a Dominant Execution Protease in Tumor Cell Apoptosis Induced by Tumor Necrosis Factor , 2001, The Journal of cell biology.

[61]  S. Alkan,et al.  Characterization of NF-κB Expression in Hodgkin’s Disease: Inhibition of Constitutively Expressed NF-κB Results in Spontaneous Caspase-Independent Apoptosis in Hodgkin and Reed-Sternberg Cells , 2001, Modern Pathology.

[62]  J. Delabie,et al.  Lymphocyte predominance Hodgkin disease is characterized by recurrent genomic imbalances. , 2001, Blood.

[63]  G. Korbutt,et al.  Mannose 6-Phosphate/Insulin-like Growth Factor II Receptor Is a Death Receptor for Granzyme B during Cytotoxic T Cell–Induced Apoptosis , 2000, Cell.

[64]  P. Isaacson,et al.  CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. , 2000, The American journal of surgical pathology.

[65]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[66]  S. Franceschi,et al.  Expression status of BCL-6 and syndecan-1 identifies distinct histogenetic subtypes of Hodgkin's disease. , 1998, Blood.

[67]  A. Kossakowska,et al.  Proteolytic activity of human non-Hodgkin's lymphomas. , 1998, The American journal of pathology.

[68]  B. Dörken,et al.  Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. , 1997, The Journal of clinical investigation.

[69]  H. Herbst,et al.  Modulation of interleukin‐6 expression in Hodgkin and Reed–Sternberg cells by Epstein–Barr virus , 1997, The Journal of pathology.

[70]  E. Ulvestad,et al.  Inhibition of phytohaemagglutinin‐induced lymphoproliferation by soluble annexin II in sera from patients with renal cell carcinoma , 1997, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[71]  J. Banchereau,et al.  Germinal Center Founder Cells Display Propensity for Apoptosis before Onset of Somatic Mutation , 1997, The Journal of experimental medicine.

[72]  P. Isaacson,et al.  Malignant lymphomas with a follicular growth pattern , 1996, Histopathology.

[73]  S. Pileri,et al.  Distinctive expression pattern of the BCL-6 protein in nodular lymphocyte predominance Hodgkin's disease. , 1996, Blood.

[74]  A. Carbone,et al.  CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin's disease. , 1995, The American journal of pathology.

[75]  U. Zabel,et al.  Nuclear uptake control of NF‐kappa B by MAD‐3, an I kappa B protein present in the nucleus. , 1993, The EMBO journal.

[76]  T. Lister,et al.  Characteristics of Sternberg-Reed, and related cells in Hodgkin's disease: an immunohistological study. , 1984, British Journal of Cancer.

[77]  W. Chan,et al.  Gcet1 (centerin), a highly restricted marker for a subset of germinal center-derived lymphomas. , 2008, Blood.

[78]  N. Perkins,et al.  Integrating cell-signalling pathways with NF-κB and IKK function , 2007, Nature Reviews Molecular Cell Biology.

[79]  N. Perkins,et al.  Integrating cell-signalling pathways with NF-kappaB and IKK function. , 2007, Nature reviews. Molecular cell biology.

[80]  M. Rebsamen,et al.  Prostaglandin E2 activates Stat3 in neonatal rat ventricular cardiomyocytes: A role in cardiac hypertrophy. , 2007, Cardiovascular research.

[81]  Y. Natkunam,et al.  Transmembrane adaptor molecules: a new category of lymphoid-cell markers. , 2006, Blood.

[82]  H. J. Kim,et al.  NF-kappaB and IKK as therapeutic targets in cancer. , 2006, Cell death and differentiation.

[83]  M. Leroy,et al.  A role for PKCzeta in the LPS-induced translocation NF-kappaB p65 subunit in cultured myometrial cells. , 2005, Biochimie.

[84]  S. Pileri,et al.  Expression of intracellular signaling molecules in classical and lymphocyte predominance Hodgkin disease. , 2004, Blood.

[85]  Michael Karin,et al.  The IKK NF-kappa B system: a treasure trove for drug development. , 2004, Nature reviews. Drug discovery.

[86]  C. Weinberg,et al.  Galectin-1: A bifunctional regulator of cellular proliferation , 2004, Glycoconjugate Journal.

[87]  R. Küppers.  Molecular biology of Hodgkin's lymphoma. , 2002, Advances in cancer research.

[88]  S. Alkan,et al.  Characterization of NF-kappaB expression in Hodgkin's disease: inhibition of constitutively expressed NF-kappaB results in spontaneous caspase-independent apoptosis in Hodgkin and Reed-Sternberg cells. , 2001, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[89]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[90]  Identification and characterization of circulating human transitional B cells , 2022 .

[91]  Nuclear Factor (cid:2) B–dependent Gene Expression Profiling of Hodgkin’s Disease Tumor Cells, Pathogenetic Significance, and Link to Constitutive Signal Transducer and Activator of Transcription 5a Activity , 2022 .